You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 134 No. 3, March 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Head & Neck Cancer
 •Genetics of Head & Neck Disease
 •Neoplasms of Head & Neck
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Role of Pyrosequencing in Head and Neck Cancer Epigenetics

Correlation of Quantitative Methylation Data With Gene Expression

Richard J. Shaw, MD, FDS, FRCS; Gillian L. Hall, MFDS; Derek Lowe, CStat; Triantafillos Liloglou, PhD; John K. Field, MA, PhD, BDS, FRCPath; Phillip Sloan, PhD, FRCPath; Janet M. Risk, PhD

Arch Otolaryngol Head Neck Surg. 2008;134(3):251-256.

Objective  To evaluate promoter methylation quantitation using recently described pyrosequencing techniques by correlation with messenger RNA (mRNA) expression.

Design  DNA was extracted from tissue samples and was subjected to bisulphite conversion. Quantitative methylation data for multiple CpG sites in each of 9 gene promoters were obtained for tumors using pyrosequencing. RNA was extracted and converted to complementary DNA, and this formed the template for relative quantitation assays of the expression of each gene by real-time reverse transcription–polymerase chain reaction.

Setting  Academic research.

Patients  Thirty-seven patients with head and neck squamous cell carcinoma.

Main Outcome Measures  The genes studied were P16 (OMIM 600160), cyclin A1 (OMIM 604036), RARB (OMIM 180220), E-cadherin (OMIM 192090), MGMT (OMIM 156569), STAT1 (OMIM 600555), ATM (OMIM 607585), hMLH1 (OMIM 120436), and TIMP3 (OMIM 188826). Immunohistochemistry was also performed for p16.

Results  STAT1, TIMP3, ATM, and hMLH1 promoters were essentially unmethylated in all cases. The data for cyclin A1 (Spearman rank correlation, {rho} = –0.53; P < .001), MGMT ({rho} = –0.53, P < .001), and RARB ({rho} = –0.34, P =.02) showed the expected negative correlation between levels of methylation and mRNA expression. The data relating to E-cadherin were inconclusive. Surprisingly, P16 expression was statistically significantly greater in those cases with higher levels of methylation ({rho} = 0.57, P < .001), a finding at odds with assumptions usually made in the literature relating gene promoter methylation to reduced gene expression. The results from p16 immunohistochemistry were in keeping with the mRNA data, but the number of positive staining samples proved too few for statistical analysis.

Conclusions  These data present a novel perspective on head and neck cancer epigenetics and reveal new and some unexpected associations and findings. The advantages of pyrosequencing over nonquantitative techniques are discussed in analyses of this nature.


Author Affiliations: Molecular Genetics & Oncology Group, School of Dental Sciences (Drs Shaw, Hall, Field, and Risk), and Cancer Research Centre, Roy Castle Lung Cancer Research Programme (Drs Liloglou and Field), University of Liverpool, and Regional Maxillofacial Unit, University Hospital Aintree (Dr Shaw and Mr Lowe), Liverpool, and Department of Oral Pathology, Turner Dental School, Manchester (Dr Sloan), England.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.